London-based biotechnology start-up Complement Therapeutics (CTx) has secured $78.9 million in Series A funding from investors. The Investors includes Cambridge Innovation Capital, Gimv, Forbion, Seroba Life Sciences, Hadean Venture, Panakes Partners, and BGV (BioGeneration Ventures). CTx is focused on the research and development of novel therapeutics for complement-mediated diseases. They have a particular focus on dry age-related macular degeneration/geographic atrophy, a leading cause of blindness.

CTx's lead investigational product, CTx001, is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy. In addition, the company has other programs in development to explore potential therapeutic opportunities in other complement-mediated conditions.

One of the unique aspects of CTx is its Complement Precision Medicine (CPM) platform. It developed as a quantification methodology to enable precise diagnosis and monitoring of diseases related to the complement cascade. The platform has the potential to quantify over 30 complement cascade proteins. They provide valuable insights into disease progression and treatment efficacy.

The funding raised in this Series A round will support CTx in advancing its research and development efforts, furthering its pipeline of novel therapeutics, and expanding its CPM platform.

CTx aims to make a significant impact in the field of complement-mediated diseases and improve the lives of patients suffering from these conditions.

For more information on Complement Therapeutics and its research and development efforts, visit their Latest funding round at https://founderlodge.com/round/Complement-Therapeutics-raises-78929000-Series-A-2023-04-18-Rafiq-Hasan-MTIyNjY